Clinical Trial Update: Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant dose-dense regimen study for early HER2-positive breast cancer was terminated, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Locally Advanced Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-08-22